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Abstract 
Objective: To investigate the clinical effectiveness of silver nitrate (95%) for the 
treatment of verruca pedis comparing professional and self-application treatments. 
Methods:  A single-centre, two-armed randomized evaluation was conducted at    a 
University podiatry clinic. A total of 113 participants (101 analysed) with ver- ruca 
pedis were included. Participants were randomized to either a  clinical  group, where 
silver nitrate was applied by a healthcare professional or a home group, where silver 
nitrate was self-applied. The main outcome measure was post-treatment pain, 
controlling for pre-treatment pain, and resolution of the verruca. Secondary outcome 
measures were participant satisfaction, partial reduction in the verruca and ease of 
use of the product. 
Key findings: The study showed no significant difference between home treat- ment 
and clinically applied treatment for the treatment of verruca pedis in either primary 
outcome; however, a substantive difference in resolution between groups was 
recorded, with 34.0% full resolution and 26.4% partial res- olution in the clinical 
treatment group, and 18.8% full resolution and 37.5% partial resolution in the home 
treatment group. Participants widely reported general ease of use of the product. All 
participants reported a reduction in pain as a result of the intervention. 
Conclusion:  Silver nitrate has been shown to be a safe and effective treatment   for 
verruca pedis, with equal success rates when compared between home and clinical 
applications. 
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Introduction 
In the UK, incidence of viral warts and verrucae in children and adolescents is estimated at 
between 3.9% and 4.9%, with both genders being equally predisposed to HPV infection 
(Leiding, 2012). The National Morbidity Survey data (1991-1992) suggests that almost two 
million people in England and Wales will see their General Practitioner for the treatment of 
cutaneous warts each year, at a cost of an estimated £40 million per annum (Thomas et al, 
2006).  
The cause of these cutaneous neoplasms is by the infection of the epidermal or mucosal 
cells with the Human Papilloma Virus (HPV) (Lynch et al, 2014).  Entry of the virus in to the 
epidermal tissue is allowed via a breach in the epidermal surface, often resulting from earlier 
microtrauma or maceration. The virus infects the basal layer of the epithelium, causing 
hyperkeratinisation and eventually a visible focal proliferation at the stratum corneum 
(Khondker et al, 2012).  The lesion can develop either singularly as a firm papule of 
hyperkeratotic tissue, or merge to form a cluster of lesions with a rough, scaly surface, which 
are referred to as ‘mosaic’.  Thickening of the stratum corneum can cause dermatoglyphics 
which are interruptions in the stratum corneum which form the lesion(s) (Lipsker, 2013).  
Discomfort caused by raised epithelial proliferations over weight-bearing areas, a negative 
social perception and the duration of recalcitrant lesions are common initiators for clinical 
treatment (Lynch et al, 2014). Several observational studies have demonstrated that most 
viral warts and verrucae will regress naturally without treatment intervention (Williams et al, 
1993) and this advice has been accepted as a valid management option (Sterling et al, 
2014).  However, the rate and success of resolution is variable and is likely to be dependent 
upon several factors, including host immunity status, age, HPV serotype, and site of infection 
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(Leiding, 2012).  Spontaneous resolution of a wart or verruca can occur at any time from a 
few months to a few years in immune-competent adults (Sterling et al 2014).   
From a clinical perspective, treatment is usually considered when lesions become 
symptomatic in terms of associated pain, enlargement or proliferation, haemorrhaging and 
causing distress (Lynch et al, 2014). Outside of these recommendations for treatment 
intervention, an expectant approach to management is often advised to patients, who are 
directed towards self-treatment with over-the-counter topical medicaments (Sterling et al, 
2014). 
Silver nitrate remains a common treatment for verrucae, especially for those patients at an 
increased risk of tissue breakdown and reduced healing capacity, due to the treatment’s self-
limiting superficial penetration into the epidermis (Kwok et al, 2012). Silver nitrate is an 
inorganic salt, classified as a caustic, anti-septic and astringent agent (Joint National 
Formulary Committee, 2015); therefore providing many uses in practice such as in the 
cauterization of wounds, removal of skin growths and granulation tissue (Monafo & Moyer, 
1965; Vermeulen et al, 2007). In the management of verrucae, the clinical aim of treatment 
involves both the biochemical and physical destruction of the virus. The application 
simultaneously instigates localized tissue irritation, thereby initiating a host immune 
response to the virus (Medicines, 2011).  
Two studies have evaluated silver nitrate against a black ink placebo for the treatment of 
verrucae and both reach similar findings (Yazar & Basaran, 1994; Ebrahimi et al, 2007). 
Yazar and Basaran reported a relatively high cure rate one month after the last application in 
the silver nitrate group (15/35, 43%) compared to 11% (4/35) in the placebo group. The 
more recent trial by Ebrahimi et al (n=60) evaluated 10% silver nitrate solution; finding a 
23.3% cure rate, compared to 0% in the placebo after 3 weeks.  There have been no 
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reported adverse side effects following the topical application of silver nitrate.  Similarly few 
contraindications exist, except for those with hypersensitivity to silver nitrate or any other 
component in the formulation. 
Strengths of 75% and 95% are frequently used in clinical practice; however, to date these 
have not been evaluated to determine their clinical effectiveness. In addition, self-
administered application of silver nitrate is now commercially available, although awareness 
of its effectiveness in comparison to the clinical application by a health professional is 
unknown (Bray, 2007). The aim of this research was to evaluate the clinical effectiveness of 
using 95% concentration silver nitrate for the treatment of verrucae pedis, comparing 
professional and self-application treatments using application pencils.  Secondary objectives 
included the collection of data relating to patient satisfaction with the treatment and the 
clinicians’ experience and opinions of using this product. 
Methods 
Trial design 
We randomized individuals in a single-centre, two-armed randomized evaluation comparing 
home and clinical application of 95% silver nitrate treatment for verruca pedis.  The 
evaluation was given ethical approval via the University School Research Ethics Panel. The 
study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as 
reflected in approval by this panel. 
Participants 
Inclusion criteria was the diagnosis of one or more verruca. Exclusion criteria were: lack of 
mobility to use the self-treatment pencils; visual difficulties; dementia or incapacity to follow 
instructions. Participants were assessed against the inclusion criteria by a Health and Care 
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Professions Council (HCPC) registered podiatrist. Participants not suited for inclusion in the 
evaluation were given a choice of an alternative course of treatment.   
Participants were recruited from advertisements placed in local GP surgeries, schools, 
health centres, podiatry private practices, around the campus of the University of 
Huddersfield and on social media sites.  The advertisement invited participants to contact 
the University Of Huddersfield Podiatry clinic via email or telephone.  The evaluation was 
carried out in the Podiatry Clinic at the University of Huddersfield, United Kingdom. 
All participants were given an information sheet prior to consent being gained. All 
participants signed a consent form and were given a set of clinical notes which were 
documented, treated and stored within the university clinical facilities, to comply with data 
protection and assure patient confidentiality.  Results from the evaluation were anonymised 
and kept on a password-protected computer, accessible only by the clinical evaluation 
personnel. A risk assessment was undertaken considering participant and clinical safety 
issues and appropriate risk management measures taken. 
Outcomes and outcome measures 
The primary outcome measures were post-treatment pain (as measured on a VAS at the 
final review of 20 weeks); and resolution of the verruca, categorized into “success” (full 
resolution of the verruca), “partial success” (up to 50% reduction in size) and “failure” (no 
change, or verruca enlarged or spread). The secondary outcome measures were participant 
satisfaction, partial reduction of the verruca and ease of use of the product.  The secondary 
outcome measures were recorded by self-completed questionnaires which were given to all 
participants. 
Interventions 
Participants included for the evaluation were given a primary treatment of debridement of 
any overlying callus.  Baseline data was obtained using a lesion chart and digital photograph 
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and the pain was recorded on a Visual Analogue Scale (VAS).  The participant was then 
randomized to either home or clinically/professionally applied treatment.   
Participants in the self-treatment arm of the evaluation were given silver nitrate pencils 
(95%) to take home and treat the verruca independently at weekly intervals for 10 weeks.  
The pack contained a silver nitrate pencil, a written instruction leaflet, a small abrasive file, 
and the clinical and emergency contact numbers in case of any localized skin irritation. The 
application method was described and demonstrated verbally, and a supplementary written 
patient advice sheet was given to all participants to ensure that they followed the same 
standardised instructions.  Participants were asked to prepare the skin prior to each 
application by using the file to remove devitalised tissue at the lesion surface.  At the end of 
the 10 week treatment period, participants were invited back the clinic by the researcher and 
assessed by an independent podiatrist, blinded to treatment arm, for an interim review,   and 
at  20 weeks after   the first application date for a final evaluation.  At both reviews the 
verruca was digitally photographed, a lesion chart completed to record size dimensions and 
border shape, and a Visual Analogue Scale (VAS) for pain score completed by the 
participant. 
The interval time for treatment application for both arms of the study was one week, as this 
was considered to be a more realistic application time based on clinical practice.   
  At these appointments, the verruca was digitally photographed, a lesion chart completed 
and a VAS completed by the participant.  This process also reflects the routine clinical 
protocol for verruca management.  If resolution had not been achieved, the lesion was 
debrided with a scalpel and silver nitrate was applied (95%). Further appointments were 
made as necessary with a maximum of 10 treatments.  As for participants in the home 
treatment arm, for the purposes of obtaining outcome measurements for the trial, at the end 
of the 10 week treatment period participants were seen by an independent podiatrist.  The 
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independent podiatrist was blind to treatment arm.  This was completed as an interim review 
and was also done after 20 weeks after the first treatment for a final evaluation.  At both of 
these reviews the verruca was digitally photographed, a lesion chart completed and a pain 
VAS completed by the participant. At both the interim or final review if verrucae were 
unresolved or a callous persisted,  debridement was carried out  
For participants in both intervention arms, the reduction or partial resolution of size of lesions 
was objectively measured by the use of a digital image with measurable parameters on the 
image and the use of a transparent lesion chart drawn over the lesion. Final judgement on 
complete resolution of all verrucae was assessed by an independent podiatrist who had not 
been involved in the study.  
At the 20 week final review, all participants were given a questionnaire to complete, at this 
appointment, about their experiences. The findings of satisfaction and ease of use are 
reported here; other findings will be reported in subsequent publications. 
Sample size 
A sample size calculation determined that under a standard level of significance (0.05) a 
total of 102 participants (51 in each arm of the trial) would be sufficient to reject the null 
hypothesis of equivalence of the population means with 80% power; assuming a medium 
sized effect on the primary outcome of post-treatment pain levels. Hence this number was 
set as the target minimum sample size to be recruited. 
Randomization 
Patients were randomized to either home or clinical treatment using the sealed opaque 
envelope method. Simple randomization without blocking was utilized. Patients could not be 
blinded to treatment allocation. 
Statistical analysis 
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The sample was summarized descriptively. Exploratory analyses were conducted to assess 
the distribution of the post-treatment VAS pain outcome and the requirement for an 
appropriate data transformation; to ensure that the frequencies of each of the categories of 
the treatment result were sufficient for analysis; and to ensure that appropriate assumptions 
were met for inferential procedures. 
An analysis of covariance (ANCOVA) was conducted on the data, using post-treatment VAS 
pain as the outcome, controlling for pre-treatment pain. An ordinal logistic regression was 
also conducted on the data, using treatment result as the outcome, with “success” defined to 
be the reference category.  
Missing resolution data was imputed under the conservative assumption of non-resolution. 
This analysis was considered to be an intention-to treat analysis and was conducted 
including all patients randomized to home treatment or clinical application. A parallel per-
protocol analysis was also conducted on participants who were followed through to analysis. 
For the pain outcome, missing data was imputed using expectation maximization; with 
parallel ITT and PP analyses also conducted. 
 
Results 
Participant flow 
Participant flow is summarized in Figure 1. 
Descriptive and exploratory analysis 
Data was collected from 113 participants recruited over the course of 12 months. There was 
no missing data on the post-VAS pain variable. Twelve cases (10.6%) had missing values 
on the treatment result variables, with respect to resolution. Little’s test for missing data 
revealed that despite the disparity of missing outcomes in the home treatment and clinical 
treatment groups, there was no evidence that missing items were not missing at random. 
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Missing values were imputed as non-resolution. The analysis of this variable was conducted 
on the remaining 101 cases as a per-parallel per protocol analysis, leading to a study with 
80% power to detect any positive benefit of one form of treatment over the other form of 
treatment. 
The sample is summarized in Tables 1 and 2.  
Analysis of data distributions and detrended Normal Q-Q plots indicated a certain degree of 
non-significant skew of the post-VAS pain variable. Reciprocal and logarithmic 
transformations did not eliminate the skew; and furthermore the large numbers of zero 
values in the original data set led to these values being disregarded in the transformed 
variables. Hence analysis was conducted on the untransformed variable. 
No relationship was found to exist between the grouping and controlling variable in the 
ANCOVA (point-biserial correlation coefficient, r=0.120; p=0.205). 
A test of parallelism found no evidence that the relationships between the grouping variable 
and the logits of the treatment result were not the same for all the logits (χ2(1)=1.49; 
p=0.222); indicating that an ordinal logistic regression analysis on this variable would be 
appropriate. 
Pain outcome 
An ANCOVA conducted on the post-VAS pain outcome measure found no evidence for a 
significant difference in post-treatment pain levels amongst participants receiving home 
treatment and participants receiving clinical treatment (F1,97=0.100, p=0.752 in the ITT 
analysis; F1,110=0.032; p=0.859 in the PP analysis). The controlling variable, pre-treatment 
VAS pain score, was significantly associated with the outcome (F1,97=41.8, p<0.001 in the 
ITT analysis; F1,110=44.7, p<0.001 in the PP analysis). The adjusted R2 value for this model 
(0.288 in the ITT analysis; 0.158 in the PP analysis) indicated that the model was a 
moderate-to-good fit to the data.  
9 
 
 
 
All participants who reported non-zero pain at baseline reported a substantive reduction in 
pain as a result of the treatment; with the ITT analysis revealing a mean pain reduction of 
3.30 points on the VAS (SD 2.46); and the PP analysis revealing a mean pain reduction of 
3.98 points on the VAS (SD 2.27)). Both analyses revealed similar levels of pain reduction in 
the home and clinical application groups which were not significantly different in the two 
groups. The ITT analysis revealed a reduction of 3.19 points on the VAS scale (SD 2.39) in 
the home treatment group, and a reduction of 3.39 points on the VAS scale (SD 2.55) in the 
clinical treatment group (p=0.717). The PP analysis revealed a reduction of 2.21 points on 
the VAS scale (SD 2.61) in the home treatment group, and a reduction of 2.77 points on the 
VAS scale (SD 2.68) in the clinical treatment group (p=0.293). 
 
Resolution outcome 
Complete resolution occurred in 27 (23.9%) of the 113 participants included in the intention-
to-treat (ITT) analysis (26.7% of the 101 patients included in the per-protocol (PP) analysis). 
An ordinal regression conducted on the treatment result variable found that there was no 
evidence that a model with group as a predictor was a significantly better fit than a null 
model with no predictors ((χ2(1)=3.18, p=0.0.075 for the ITT analysis; χ2(1)=1.22,p=0.269 for 
the PP analysis). However, a substantive difference in favour of clinic treatment was 
observed with respect to the treatment result outcome: participants randomised to the clinic 
group had a greater resolution success of 18 out of 55 participants (32.7%) compared to 9 
out of 58 participants (15.5%) in the home treatment group in the ITT analysis; and 18 out of 
53 participants (34.0%) compared to 9 out of 48 participants (18.8%) in the home treatment 
group in the PP analysis. Additionally, a further 18 participants (31.0%) in the home 
treatment group and 14 participants (25.5%) in the clinic group showed a 50% reduction in 
size of verrucae in the ITT analysis.  
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Secondary outcomes 
44 out of 58 participants from the home treatment arm and 39 out of 55 participants from the 
clinic treatment arm completed the questionnaires. 19 out of 42 participants (45.3% of valid 
responses) found the treatment “easy” or “very easy” to apply. Only 6 patients (14.3%) found 
the treatment “difficult” or “impossible” to apply. Application instructions were 
correspondingly rated well, with all participants rating them as “OK” or better.  
Overall, 30 out of 40 participants (75.0%) rated themselves satisfied with home treatment; 32 
out of 38 participants rated themselves satisfied with clinic treatment. This difference in 
proportions was not clinically significant (p=0.788). 
Discussion 
The findings of this evaluation confirm that there is no evidence that whether a patient 
receives home or clinic treatment has any significant effect on post-treatment pain score, 
controlling for pre-treatment pain levels.  Both arms of the evaluation indicate a positive 
benefit of the treatment, regardless of whether applied at clinical or at home, measured in 
terms of pain reduction, verruca resolution and patient satisfaction.  
Despite the observed difference in outcomes (in terms of degree of resolution) between the 
treatment groups, the findings also confirm that there is no evidence that home treatment 
and clinical treatment are statistically different in effectiveness.  
Strengths and limitations 
This randomized evaluation was not registered as a clinical trial.  RCTs may still be 
considered by many to be the strongest form of evidence for clinical decision making (Steen 
& Dager, 2013).  Close matching of participants on demographic characteristics across both 
treatment arms following randomisation eliminates the influence of these variables on the 
assessment of the effectiveness of treatment regime. However, the lack of a control group 
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precludes definitive statements relating to the effectiveness of sliver nitrate per se in the 
current study, in which a total of 38 (34%) participants recruited had had a verruca for less 
than one year. It has been reported that 30% of warts resolve without treatment by 32 weeks 
(de Haen et al, 2006), and hence it could be argued that a proportion of these lesions 
included in the analysis would have shown spontaneous regression even without any 
intervention. Furthermore 33% of participants had had a verruca for 5 years and over, and 
had tried numerous other treatments such as acids without success.  De Haen et al 
highlights that some verrucae may be particularly resistant to not only spontaneous 
resolution, but to any treatment. Both arguments suggest that it is possible that the success 
rate of silver nitrate could have been over- or underestimated due to the lack of comparison 
to a control. According to Gibbs and Harvey (2009), a ‘wait and see’ approach or placebo 
group has a success rate of around 30%. Bristow and Greenwood (2009) argue the 
proposed treatment must therefore be significantly greater than this figure to be considered 
effective.  
Participants in both arms of this evaluation were assessed at week 20 (approximately 10 
weeks after the last treatment), by podiatrist independent of and impartial to the evaluation, 
effectively blinded to the treatment arms.  This assessment sought to gain an objective view 
of whether the verruca had resolved, partially resolved or remained the same.  Kwok et al 
(2012), however, recommends a follow-up interval of 6 months to fully assess complete 
resolution or recurrence, given that the virus can have a latent configuration. Assessment at 
six months would not only have allowed for the fact that the human papilloma virus may 
remain dormant within epithelial cells without visible disease, but would also allow time for 
any response mediated by the immune system to be observed.  Therefore it is possible that 
patients who showed a significant reduction in the size of lesions may have seen a complete 
resolution if treatment were continued after the 10 week cut-off for the evaluation period.  
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Keefe & Dick (1990) used a questionnaire to look at long-term outcomes and found that 83% 
of participants believed they were cured at the end of the treatment period, but only 57% 
were cleared of warts after a median follow-up time of 19 months. 
The assumption that those patients for whom resolution data at outcome was missing had 
non-resolved verruca is thought to be conservative. The most likely reason for a patient 
failing to attend a follow-up appointment is that their verruca had been resolved to their 
satisfaction. Even so, the findings of the trial were not sensitive to this assumption, with both 
the ITT and PP analyses concluding lack of evidence for a difference in home and clinical 
application with respect to this outcome. Findings related to the pain data were also not 
sensitive to missing data items on this outcome.  
 
Comparison of findings against other studies 
The full resolution rate in the current study of 34.0% and 18.8% in the clinical and home 
treatment groups are broadly comparable with the findings of earlier studies of the efficacy of 
silver nitrate (Yazar and Basaran, 1994; Ebrahimi et al, 2007). Direct comparisons of 
resolution rates cannot be drawn between these two studies and this evaluation due to 
differences in the concentration of silver nitrate used; for instance Ebrahimi et al (2007) 
investigated a solution of 10%.  A comparison of clearance results from other clinical-based 
treatments also indicates similar results to the findings of the current study: resolution rates 
of 33.7% were reported by Cockayne et al (2012); of 39% by Sjoerd et al (2010); of 9% by 
Gibson et al (1984); and of 47% and 44% by Ahmed et al (2001) in cryotherapy groups; and 
of 42% by Khattar et al. (2007) and 24% by Sjoerd et al (2010) in salicylic acid groups. 
These findings suggest that silver nitrate treatment can compete against other clinical 
interventions in the treatment of verrucae pedis. However clinical heterogeneity restricts the 
validity of direct comparisons between studies.  
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 Implications for clinical practice 
This randomized evaluation of the clinical effectiveness of silver nitrate (95%) for the 
treatment of verruca pedis revealed no evidence for a significant effect of treatment 
environment (home or clinic treatment) on either post-operative pain score or treatment 
result. Although the health economics data was not established, silver nitrate is a safe, cost-
effective and easy to use treatment option for verruca.  It is suitable for application for any 
patient profile, offering the clinician an alternative option for treatment.  Future research 
could focus on comparing the resolution rates of silver nitrate against other commercially 
available treatment modalities.  
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Figures   
Figure 1: Participant Flow Diagram 
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Tables: Table 1: descriptive summary of sample 
Factor Frequency (valid %) 
Home treatment 
(N=58) 
Clinic treatment 
(N=55) 
All participants 
(N=113) 
Gender 
   Male 
   Female 
 
23 (39.7%) 
35 (60.3%) 
 
21 (38.2%) 
34 (61.8%) 
 
44 (38.9%) 
69 (61.1%) 
Location 
   Forefoot 
   Forefoot, plus mid and/or 
rearfoot    
   Rearfoot   
 
37 (63.8%) 
13 (22.4%) 
 
8 (13.8%) 
 
33 (60.0%) 
12 (21.8%) 
 
10 (18.2%) 
 
70 (61.9%) 
25 (22.2%) 
 
18 (15.9%) 
Duration 
   Less than 1 year 
   1-4 years 
   5 years and over 
 
25 (43.1%) 
16 (27.6%) 
17 (29.3%) 
 
13 (24.1%) 
21 (38.9%) 
20 (37.0%) 
 
38 (34.0%) 
37 (33.0%) 
37 (33.0%) 
 
Table 2: Primary and 
Secondary Outcome 
Results 
Home treatment Clinic treatment All participants 
 Numerical Variable - Mean (SD) 
Age (years) 42.8 (22.8) 43.8 (21.6) 43.3 (22.1) 
Result 
   Success 
   Partial success 
   No 
change/enlargement 
 
9 (18.8%) 
18 (37.5%) 
21 (43.8%) 
 
18 (34.0%) 
14 (26.4%) 
21 (39.6%) 
 
27 (26.7%) 
32 (31.7%) 
42 (41.6%) 
Pre-treatment VAS 
pain score 
3.24 (3.12) 3.98 (3.05) 3.61 (3.09) 
Post-treatment VAS 
pain score at 10 or 
20 week review 
0.948 (1.81) 1.25 (2.07) 1.10 (1.94) 
Change in VAS pain 
score 
2.29 (2.58) 2.72 (2.66) 2.50 (2.62) 
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